The present invention relates to lymphocytes, preferably that have been transinfected from dendritic cells with a bacterium, preferably CD4+ T cells, preferably Listeria monocytogenes, wherein said bacterium comprises a tumor peptide. It also relates to the use of lymphocytes for therapy and/or treatment of solid tumors, preferably melanoma, the kit or device that comprises same for this purpose. Furthermore, it also refers to the transinfection method thereof.
